Reduced urine pregnenolone concentration after clinical response in patients with depression: An open-label short-term prospective study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023761%3A_____%2F23%3AN0000010" target="_blank" >RIV/00023761:_____/23:N0000010 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/j.psyneuen.2023.106366" target="_blank" >https://doi.org/10.1016/j.psyneuen.2023.106366</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.psyneuen.2023.106366" target="_blank" >10.1016/j.psyneuen.2023.106366</a>
Alternative languages
Result language
angličtina
Original language name
Reduced urine pregnenolone concentration after clinical response in patients with depression: An open-label short-term prospective study
Original language description
Background: Identifying biological alterations in patients with depression, particularly those that differ between responders and non-responders, is of interest to clinical practice. Biomarker candidates involve neuroactive steroids, including pregnenolone (PREG) and allopregnanolone (ALLO). However, alterations in PREG and ALLO associated with treatment response are understudied. This study's main aim was to evaluate the effects of antidepressant treatment, clinical response, and treatment duration on PREG and ALLO in depression.Materials and Methods: In a 4-week, open-label trial, participants were allocated randomly to the venlafaxine (n = 27) or mirtazapine (n = 30) group. Urine concentrations of PREG and ALLO were assessed through gas chromatography-mass spectrometry. Participants collected night urine between 10:30 p.m. and 8:00 a.m. Two primary outcomes were analyzed. Firstly, the effect of treatment (mirtazapine or venlafaxine), clinical response (operationalized through the Hamilton Depression Rating Scale), and time (baseline compared to 28 days) on the urine concentrations of PREG or ALLO in depression. Finally, the effect of clinical response and time on the urine concentration of PREG or ALLO, independently of the antidepressant given (mirtazapine or venlafaxine). Linear mixed models were carried out.Results: There was no significant difference in PREG and ALLO concentrations between baseline and 28 days in responders and non-responders when investigating the venlafaxine or the mirtazapine group. However, we found a significant reduction of urine PREG concentration after 28 days of treatment in responders who received either venlafaxine or mirtazapine (estimate =-0.56; p = 0.016; 95CI [-1.003;-0.115]; Cohen's d =-0.61).Conclusions: Our main results indicate that responders in depression show reduced urinary PREG concentrations after 4-weeks of therapy, independently of the antidepressant used. More studies are needed to confirm these findings.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Psychoneuroendocrinology
ISSN
0306-4530
e-ISSN
1873-3360
Volume of the periodical
157
Issue of the periodical within the volume
November
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
106366
UT code for WoS article
001065484800001
EID of the result in the Scopus database
2-s2.0-85168586515